Business Context and Reporting Period
Company: The Clorox Company (CLX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 2025 (Fiscal Year 2025)
Business Overview: A leading multinational manufacturer of consumer and professional products including cleaning, disinfecting, household, lifestyle, and international brands. The company operates through four reportable segments: Health and Wellness, Household, Lifestyle, and International.
Key Financial Metrics
| Metric ($ millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Sales | $1,668 | $1,814 | $5,116 | $5,190 |
| Gross Profit | $744 | $766 | $2,289 | $2,164 |
| Gross Margin | 44.6% | 42.2% | 44.7% | 41.7% |
| Net Earnings (Attributable to Clorox) | $186 | $(51) | $478 | $64 |
| Diluted EPS | $1.50 | $(0.41) | $3.84 | $0.52 |
| Operating Cash Flow (9M) | $687 | $355 | N/A | N/A |
| Cash and Equivalents (End of Period) | $226 | N/A | N/A | N/A |
| Total Debt (Short + Long Term) | $2,537 | N/A | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 8% in Q3 and 1% over nine months, primarily driven by the divestiture of the Better Health VMS business (completed Sept 2024) and the Argentina business (completed March 2024).
- Profitability Surge: Net earnings turned from a loss of $51 million in Q3 2024 to a profit of $186 million in Q3 2025. This improvement is largely due to the absence of a $240 million loss on the Argentina divestiture and a $171 million pension settlement charge recorded in the prior year.
- Margin Expansion: Gross margin improved by 240 basis points in Q3 and 300 basis points over nine months, driven by cost savings and the removal of lower-margin divested businesses.
- Cyberattack Impact: The company recorded $35 million in insurance recoveries in Q3 2025 related to the August 2023 cyberattack, compared to $8 million in incremental costs in the same period last year. Operations have normalized.
- Divestitures: Recorded an after-tax loss of $118 million in the nine months ended March 31, 2025, related to the Better Health VMS divestiture.
Guidance, Outlook, and Risks
- Outlook: Management anticipates a volatile operating environment due to macroeconomic uncertainty, potential tariffs, and geopolitical instability. The company expects to continue driving growth and rebuilding margins through its streamlined operating model.
- Liquidity and Debt:
- Current liabilities exceed current assets by $565 million, primarily due to a $515 million obligation to purchase P&G's 20% interest in the Glad venture, due in January 2026.
- On March 25, 2025, the company entered a new $1.2 billion revolving credit agreement maturing in 2030. No borrowings were outstanding under this facility as of March 31, 2025.
- Capital Allocation:
- Repurchased 1.7 million shares for $257 million during the nine months ended March 31, 2025.
- Declared dividends of $1.22 per share for Q3 2025.
- Risks: Key risks include supply chain disruptions, raw material cost volatility, foreign exchange fluctuations, and the successful implementation of new digital capabilities (ERP system) which may impact internal controls.
Investor Verification Checklist
- Divestiture Accounting: Verify the treatment of the $118 million loss on the Better Health VMS divestiture and its impact on future comparability.
- Glad Venture Obligation: Confirm the funding strategy for the $515 million payment due to P&G in January 2026 and the sensitivity of the fair value estimate to discount rate changes.
- Cyberattack Residuals: Assess if any further costs or insurance recoveries related to the August 2023 cyberattack are expected in future periods.
- Organic Growth: Distinguish between reported sales declines and organic sales growth (reported as -2% for Q3 and +4% for 9M) to understand underlying business performance.
- ERP Implementation: Monitor the progress and cost of the new ERP system implementation, which is expected to continue through fiscal 2026.